Arcadia Biosciences faces Nasdaq equity shortfall
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
Arcadia Biosciences filed an S-8 registration for employee-plan shares while facing a Nasdaq compliance issue, as stockholders' equity sits below the USD 2.50 million minimum. The company posted second-quarter revenue of USD 1.44 million and a net loss of USD 6.27 million, with third-quarter results due November 5, 2026.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.